Loading
Loading
Metabolic & Body Composition · 20mg + 40mg
Choose dose
10 vials per kit
Retatrutide + Tirzepatide is a research peptide combination of Retatrutide 20mg and Tirzepatide 40mg (60mg total per vial) studied in preclinical research for overlapping incretin-pathway activity. Retatrutide is a triple GLP-1/GIP/glucagon receptor agonist studied for energy expenditure and appetite regulation; Tirzepatide is a dual GIP/GLP-1 receptor agonist studied for glycaemic control and body composition. Research has examined combined receptor engagement across metabolic and weight-management endpoints.
Blended compound — purity note
Peptide blends are not tested for combined purity as a single compound. However, every component is sourced from the same supplier as our individual peptide products, all of which carry valid Janoshik Analytical COAs. Those certificates apply equally to the same peptides in this blend. View individual COAs →
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties · Retatrutide
Chemical Properties · Tirzepatide
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Retatrutide
Retatrutide (LY3437943) is a triple incretin receptor agonist — the first synthetic peptide to simultaneously target GLP-1, GIP, and glucagon receptors (GcgR) in a single molecule. Developed by Eli Lilly, it represents the third generation of incretin pharmacology beyond dual agonists, adding a thermogenic dimension through glucagon receptor engagement that earlier generations lack.
Retatrutide activates all three receptors with approximately equipotent nanomolar affinity. GLP-1R engagement contributes appetite suppression and glucose-dependent insulin secretion. GIPR engagement adds adipose tissue effects and amplifies the GLP-1R appetite signal. Crucially, glucagon receptor activation stimulates energy expenditure through GcgR-mediated thermogenesis and lipolysis — an effect counterbalanced by concurrent GLP-1R activity that prevents net hyperglycaemia. This triple mechanism distinguishes retatrutide from dual agonists in both the magnitude of weight loss and the composition of weight lost.
Phase 2 data published in the NEJM (2023) demonstrated up to 24.2% body weight reduction at 48 weeks — among the highest observed for any pharmacological agent in obesity trials. Research continues into non-alcoholic fatty liver disease/NASH, dyslipidaemia, insulin resistance, and cardiovascular risk reduction. The glucagon component makes retatrutide a candidate for hepatic conditions where glucagon signalling plays a regulatory role.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
